Imaging technologies in urology have become integral tools for diagnosing and treating various urinary and reproductive ...

Teleflex Incorporated TFX posted fourth-quarter 2024 adjusted earnings per share (EPS) from continuing operations of $3.89, ...

The 18-gene MyProstateScore 2.0 biomarker test was designed to reduce overdiagnosis of low-grade prostate cancers.

Teleflex to create a new, independent publicly traded company consisting of its Urology, Acute Care, and OEM businesses.

The following is a summary of “Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic ...

According to the report, just two weeks before filing for bankruptcy TUCC and its former CEO John Tillett, MD, were sued by Cedar Rapids, Iowa-based Ark Data Centers, a data security company that ...

The Deanne Reeve Pelvic Health Suite is the first of its kind in Atlantic Canada and brings some urology and gynecology ...

As per NCCN [National Comprehensive Cancer Network], high-risk prostate cancer is defined by a PSA [prostate-specific antigen] >20 mg/mL, a Gleason score of 8 to 10, or a clinical tumor stage of T3 or ...

Teleflex to separate into two companies by mid-2026 and acquire Biotronik's Vascular Intervention unit for €760 million. CFO ...

MPS2 provides meaningful improvement in detection of grade group ≥2 cancer relative to PSA-based testing approaches.

Teleflex (NYSE: TFX) announced today that it plans to separate its Urology, Acute Care and OEM businesses into a new publicly ...